187 related articles for article (PubMed ID: 2182910)
1. Functional contribution of cysteine residues to the human immunodeficiency virus type 1 envelope.
Tschachler E; Buchow H; Gallo RC; Reitz MS
J Virol; 1990 May; 64(5):2250-9. PubMed ID: 2182910
[TBL] [Abstract][Full Text] [Related]
2. Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage.
Guo HG; Veronese FM; Tschachler E; Pal R; Kalyanaraman VS; Gallo RC; Reitz MS
Virology; 1990 Jan; 174(1):217-24. PubMed ID: 2104682
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.
Grimaila RJ; Fuller BA; Rennert PD; Nelson MB; Hammarskjöld ML; Potts B; Murray M; Putney SD; Gray G
J Virol; 1992 Apr; 66(4):1875-83. PubMed ID: 1548744
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160.
Freed EO; Myers DJ; Risser R
J Virol; 1989 Nov; 63(11):4670-5. PubMed ID: 2677400
[TBL] [Abstract][Full Text] [Related]
5. Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin.
Pincus SH; Wehrly K; Tschachler E; Hayes SF; Buller RS; Reitz M
J Exp Med; 1990 Sep; 172(3):745-57. PubMed ID: 1696955
[TBL] [Abstract][Full Text] [Related]
6. Effects of mutations in glycosylation sites and disulphide bonds on processing, CD4-binding and fusion activity of human immunodeficiency virus envelope glycoproteins.
Bolmstedt A; Hemming A; Flodby P; Berntsson P; Travis B; Lin JP; Ledbetter J; Tsu T; Wigzell H; Hu SL
J Gen Virol; 1991 Jun; 72 ( Pt 6)():1269-77. PubMed ID: 2045792
[TBL] [Abstract][Full Text] [Related]
7. CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion.
Broder CC; Berger EA
J Virol; 1993 Feb; 67(2):913-26. PubMed ID: 8419649
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.
Freed EO; Myers DJ; Risser R
Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4650-4. PubMed ID: 2191297
[TBL] [Abstract][Full Text] [Related]
9. Analysis of endoproteolytic cleavage and intracellular transport of human immunodeficiency virus type 1 envelope glycoproteins using mutant CD4 molecules bearing the transmembrane endoplasmic reticulum retention signal.
Raja NU; Vincent MJ; Jabbar MA
J Gen Virol; 1993 Oct; 74 ( Pt 10)():2085-97. PubMed ID: 8409933
[TBL] [Abstract][Full Text] [Related]
10. Conserved cysteine residues in the human immunodeficiency virus type 1 transmembrane envelope protein are essential for precursor envelope cleavage.
Dedera D; Gu RL; Ratner L
J Virol; 1992 Feb; 66(2):1207-9. PubMed ID: 1731099
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of two distinct cytopathic effects with syncytium formation-defective human immunodeficiency virus type 1 mutants.
Dedera D; Ratner L
J Virol; 1991 Nov; 65(11):6129-36. PubMed ID: 1717715
[TBL] [Abstract][Full Text] [Related]
12. Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.
Freed EO; Myers DJ; Risser R
J Virol; 1991 Jan; 65(1):190-4. PubMed ID: 1985197
[TBL] [Abstract][Full Text] [Related]
13. Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.
Chiou SH; Freed EO; Panganiban AT; Kenealy WR
AIDS Res Hum Retroviruses; 1992 Sep; 8(9):1611-8. PubMed ID: 1457207
[TBL] [Abstract][Full Text] [Related]
14. Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity.
Page KA; Stearns SM; Littman DR
J Virol; 1992 Jan; 66(1):524-33. PubMed ID: 1727497
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of the conserved cysteine residues in the simian immunodeficiency virus matrix protein.
González SA; Affranchino JL
Virology; 1995 Jul; 210(2):501-7. PubMed ID: 7618287
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus type 1 Vpu protein induces degradation of chimeric envelope glycoproteins bearing the cytoplasmic and anchor domains of CD4: role of the cytoplasmic domain in Vpu-induced degradation in the endoplasmic reticulum.
Vincent MJ; Raja NU; Jabbar MA
J Virol; 1993 Sep; 67(9):5538-49. PubMed ID: 8350411
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of human immunodeficiency virus type 1 variants diminished in the ability to induce syncytium-independent cytolysis.
Stevenson M; Haggerty S; Lamonica C; Mann AM; Meier C; Wasiak A
J Virol; 1990 Aug; 64(8):3792-803. PubMed ID: 1695254
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus infection and syncytium formation in HeLa cells expressing glycophospholipid-anchored CD4.
Kost TA; Kessler JA; Patel IR; Gray JG; Overton LK; Carter SG
J Virol; 1991 Jun; 65(6):3276-83. PubMed ID: 1709701
[TBL] [Abstract][Full Text] [Related]
19. Impact of natural sequence variation in the V2 region of the envelope protein of human immunodeficiency virus type 1 on syncytium induction: a mutational analysis.
Andeweg AC; Boers PH; Osterhaus AD; Bosch ML
J Gen Virol; 1995 Aug; 76 ( Pt 8)():1901-7. PubMed ID: 7636471
[TBL] [Abstract][Full Text] [Related]
20. Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160.
Berman PW; Riddle L; Nakamura G; Haffar OK; Nunes WM; Skehel P; Byrn R; Groopman J; Matthews T; Gregory T
J Virol; 1989 Aug; 63(8):3489-98. PubMed ID: 2545918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
